AbbVie Inc., US00287Y1091

AbbVie stock after-hours at EUR 232.05: plus 0.19 percent versus prior close

Published on 10/01/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock was at EUR 232.05 after-hours at 7:22 p.m. CEST on October 1, up 0.19 percent versus the prior close. AbbVie also reported new RINVOQ vitiligo data.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung
AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie stock was at EUR 232.05 after-hours at 7:22 p.m. CEST on October 1, 2026, up 0.19 percent versus the prior close at Lang & Schwarz.

Trading after the Xetra close

The prior close at Lang & Schwarz was EUR 231.60 on September 30, 2026. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of AbbVie Inc. stock.

RINVOQ vitiligo data

AbbVie said on October 1 that ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies showed continued facial and total-body repigmentation through week 76 among patients continuing RINVOQ. In Viti-Up-1, the proportion reaching the F-VASI 75 measure increased from 33.1 percent at week 48 to 55.1 percent at week 76; in Viti-Up-2, it increased from 27.6 percent to 47.4 percent. The data were presented at the 2026 European Academy of Dermatology and Venereology Congress.

Third-quarter reporting date

AbbVie said in a PR Newswire release dated October 1 that it will announce third-quarter 2026 financial results before the market opens on Friday, October 30, 2026. The company said its earnings conference call will begin at 8 a.m. Central time.

Disclaimer...

en | US00287Y1091 | ABBVIE INC. | boerse | 70212162 | bgmi